



# Coping with Analytical Interferences

## (Handling Icteric, Hemolytic and Lipaemic Samples)

Graham Jones

Department of Chemical Pathology

St Vincent's Hospital, Sydney

**Surabaya Indonesia 2016**

# Acknowledgements



ASIA-PACIFIC FEDERATION FOR CLINICAL BIOCHEMISTRY  
AND LABORATORY MEDICINE



# Contents


- Background
- Laboratory protocols for common interferences
- Method Evaluation
- Planning to handle common interferences

# Background

- Our aim: to produce timely, accurate results to allow optimal patient care
- “Accuracy”: results which reflect the *in-vivo* concentration of an analyte
- Interferents - substances present in a sample, or events affecting a sample, which lead to the production of inaccurate results

# Interferences

- May be caused by factors:



- May affect:

- All results in collection
- Some results in collection
- Only one result from collection

# In the patient ...

- Icterus
- Lipaemia
- Heterophile antibodies
- “Macro-things” Eg macro prolactin, macro-CK
- Other antibody effects (eg precipitation in phosphate assay)
- Drugs

# In the collection...

- Wrong patient
- Wrong label
- Wrong tube
- Drip-arm
- Prolonged tourniquet
- In-vitro haemolysis
- Delayed separation
- Improper handling

# In the collection...

- Wrong patient

- Wrong time

- D

- P

- I

- D

- I

**SOLUTIONS: 1 – In the Collection:**

**MINIMISE ERROR RATE**

**Education / training**

**Resources (correct equipment; information)**

**Specialist collectors**

**Monitor and improve**



# Error Importance

- **Erroneous and Non-believable**
  - eg potassium of 20 mmol/L due to gross haemolysis or EDTA contamination
  - Clinical result: **ignore or recollect specimen**
- **Erroneous and Believable**
  - eg potassium of 5.5 mmol/L due to mild haemolysis
  - Clinical result: **wrongly stop potassium supplements**

# Interferences: Two Types

- **Visible Interferences**
  - Haemolysis, lipemia, icterus
- **Other Interferences**
  - Non-visible interferences  
(the rest)

# Visible Interferents



- Examples of common visible interferences.
- Haemolysis, Icterus, Lipaemia
- Detectable by scientists and instruments



# In-Vitro Haemolysis



Caused by damage to red cells during collection or handling  
Releases red cell contents into serum / plasma


# In-Vitro Haemolysis

Most common in the first sample collected in the ED

At time of insertion of cannula.

Collection through plastic, flexible  
cannula in thin-walled vein

(not firm steel needle in large antecubital vein)





“Sucking” of vessel wall onto cannula → sheer stress  
→ in-vitro haemolysis

Can affect over 5% of ED samples (fewer from other places)



Also squirting blood through needle into tubes (DO NOT DO)

# Haemolysis interference - mechanisms

# Release of analyte from with red cell





# Dilution of analyte: Sodium








# Release of analogue: Creatine Kinase



# Spectral and Chemical interference: bilirubin



# No effects: Urea, Glucose




[Haemoglobin] (mg/dL)

# Laboratory Interference Protocols

1. Identify presence of interferent
2. Quantify interferent  
Visual, Automated
3. Specify response to interferent
  - Lead to reproducible response
  - Simple to administer

# Identify/Quantify: Visual Interference Chart

## HAEMOLYSIS INTERFERENCE CHART




Colour Chart for Comparison of tubes to determine severity of haemolysis.

Haemoglobin expressed in mg/dL.

# Instrument Detection

- “Serum Indices”
- Based on absorbance at various wavelengths
- Vary between instruments
- May be quantitative or semi-quantitative
- Often without units
- Instruments
  - Roche, Siemens, Beckman-Coulter, Abbott (chemistry not immunoassay)
  - Others ....?


# Haemoglobin, Bilirubin, Lipaemia - spectra



# Haemolysis Protocol

(based on serum indices)

Haem (mg/dL)	Analyte
30	LDH
40	LD1
100	Potassium
130	AST, CK
160	Bilirubin, c.Bili
350	Phosphate
500	Fructosamine, Iron
600	Protein
700	Triglycerides
800	Albumin, ALT, GGT, Cholesterol
1000	Amylase, ALP, Bicarbonate, Calcium, CK-MB, Lipase, HDL, Magnesium
1200	Sodium
1500	Uric Acid
2000	Chloride, Creatinine, Glucose, Transferrin, Urea





# Response to Interferents

- Release result with a comment
- With-hold result (with a comment)
- Alternate strategies
  - Recollect (haemolysis only)
  - Remove interferent (lipaemia)
  - Different method (lipaemia and sodium)
  - Correct for effect (haemolysis)


# Release with a Comment (examples)

- “Specimen haemolysed”
- “Mildly haemolysed specimen, interpret with caution”
- “Specimen slightly haemolysed. LD rises with haemolysis. Potassium may also increase.”
- “Mildly haemolysed specimen. Results of K, Phosphate, TCO<sub>2</sub>, bilirubin, AST, GGT, CK, LDH, Fe and Amylase are affected.”


# Haemolysis Protocol

(based on serum indices)

Haem (mg/dL)	Analyte
30	LDH
40	LD1
100	Potassium
700	Triglycerides
800	Albumin, ALT, GGT, Cholesterol
1000	Amylase, ALP, Bicarbonate, Calcium, CK-MB, Lipase, HDL, Magnesium
1200	Sodium
1500	Uric Acid
2000	Chloride, Creatinine, Glucose, Transferrin, Urea



**“Potassium: No result due to interference from mild haemolysis.”**



# Release Corrected results

- More results available, more quickly
- Depends on accuracy of correction
- Fewer recollections
- SydPath: Potassium, CK, Troponin T  
*(not widely done!)*



**Correcting laboratory results for the effects of interferences: an approach incorporating uncertainty of measurement**

Annals of Clinical Biochemistry 2015;52:226-31

Graham RD Jones<sup>1</sup> and Robert C Hawkins<sup>2</sup>

# Interference Planning

- (choice of instrument / reagents)
- Evaluate current instrument / reagents
- Define Allowable Error
- Set limits for interferents
- Define response to excessive interference

# Evaluate Instruments / Methods

- Source material
  - Manufacturers claims\*
  - Published evaluations
  - Local Studies
  
- \*Manufacturers claims
  - Review criteria for “no effect”
  - May be limited in testing range

# Manufacturer - Example

## **Limitations – interference<sup>12,15</sup>**

For determination of cholesterol with lipase on Roche/Hitachi 704/717 analyzers, refer to the R1/R2 application in the Instrument Settings section.

US users: Refer to application sheet.


Criterion: Recovery within  $\pm 10\%$  of initial values.

Icterus: No significant interference up to an I index of 25 (approximate conjugated bilirubin concentration: 25 mg/dl or 428  $\mu\text{mol/l}$ ) and an I index of 10 (approximate unconjugated bilirubin concentration: 10 mg/dl or 171  $\mu\text{mol/l}$ ).


Hemolysis: No significant interference up to an H index of 700 (approximate hemoglobin concentration: 700 mg/dl or 435  $\mu\text{mol/l}$ ).

# Method differences

## Phosphate



## Bilirubin




Haemoglobin (mg/dL)

Haemolysis effect for 7 methods on 2 analytes.  
**NOT ALL METHODS THE SAME.**



# Interferogram



Haemoglobin (mg/dL)

- Haemolysis Effect
- Roche Modular P
- Haemolysate added to sample
- Percent measured plotted against haemoglobin
- (Melvin Glick)

# Define Allowable Error

- RCPA-AACB Quality Assurance limits
- Change greater than 2 SD of analytical precision
- Change related to biological variation
- 10%
- Other fixed percentage or absolute values
- A difference that may lead to a change in clinical management - subjective\*


# The Accuracy - Utility Balance

## Tighter Limits

More accuracy  
More rejections  
More recollections  
More delays  
Unhappier ptns  
and Drs  
Fewer clinical  
errors

## Looser Limits


Less accuracy  
Fewer rejections  
Fewer recollections  
Shorter TAT  
More clinical errors



# Other factors

- Intravascular haemolysis
- With-holding potentially useful results
- Releasing erroneous results
  
- Effect of concentration

# Absolute Limits



# Summary

- Interferences affect our core function in  
rou **SOLUTIONS: 2 – Visible interferences:**
- Lab **LABORATORY PROTOCOL**  
ide  
hae **Identify**  
**Quantify**  
**Respond**  
Pla  
ins  
your clients. **- with-hold, comment, correct, other**

# Non-Visible Interferences

# Non-Visible Interferences

- Wrong patient, Wrong tube, Aliquoting error
- Drip-arm, Prolonged tourniquet
- Delayed separation, Improper handling
- Heterophile antibodies
- “Macro-things” Eg macro prolactin
- Other antibody effects (eg precipitation in phosphate assay)
- Drugs



# Non-Visible Interferences

- Not apparent until results obtained
- May see:
  - Extreme results
  - Patterns: eg ETDA, drip arm, delayed separation
  - Changes since last measurement (delta)

# Non-Visible Interferences

- Only tool: Results Review

- I **SOLUTION 3 – Non-visible interferences:**

- I

- I **LABORATORY PROTOCOL**

**Result Review**

**Identify likely cause**

- I **Respond**

**- check results, recollect, d/w team**

- Communicate with requester

# Summary

- Interferences affect our core function in routine pathology laboratories.
- Laboratories must have protocols for:
  - Collecting samples correctly
  - Identifying, quantifying and responding to “coloured” samples.
  - Identifying, evaluating and responding to unusual patterns of results.
- Best practice involves communication of processes and results with clinicians

# End

## **Handling Common Interferences.**

Graham Jones

Clin Biochem Revs, 2002;23:101-128.